Study to Evaluate the Inflammatory Cells Activity in Patients With Persistent Asthma Treated With Montelukast (0476-403)(COMPLETED)
NCT ID: NCT00770900
Last Updated: 2010-12-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
83 participants
INTERVENTIONAL
2008-09-30
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Montelukast
Asthmatic children and teenagers took montelukast daily.
montelukast sodium
Asthmatic children and teenagers took montelukast daily for 12 weeks.
Children aged 2-5 years took 4mg tablet of montelukast
Children aged 6-15 years took 5mg tablet of montelukast
Children \>15 years took 10mg tablet of montelukast
Placebo
Placebo to montelukast tablet daily.
Comparator: placebo comparator
Asthmatic children and teenagers took Placebo tablet daily for 12 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
montelukast sodium
Asthmatic children and teenagers took montelukast daily for 12 weeks.
Children aged 2-5 years took 4mg tablet of montelukast
Children aged 6-15 years took 5mg tablet of montelukast
Children \>15 years took 10mg tablet of montelukast
Comparator: placebo comparator
Asthmatic children and teenagers took Placebo tablet daily for 12 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Brasilia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Merck Sharp & Dohme Corp
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK0476-403
Identifier Type: -
Identifier Source: secondary_id
2008_563
Identifier Type: -
Identifier Source: org_study_id